Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Huh

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
Journal of Pediatric Gastroenterology and Nutrition|October 26, 2018
Pediatric Feeding Disorder: Consensus Definition and Conceptual FrameworkPraveen S Goday, Susanna Y Huh, Alan Silverman, et al.
International Journal of Epidemiology|March 19, 2014
Cohort profile: project vivaEmily Oken, Andrea A Baccarelli, Diane R Gold, et al.
Circulation|July 13, 2016
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria SyndromeLeslie B Gordon, Monica E Kleinman, Joe Massaro, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 2006
An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized ratsM K Kim, H D Kim, J H Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndromeLeslie B Gordon, Monica E Kleinman, David T Miller, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
Journal of Pediatric Gastroenterology and Nutrition|October 26, 2018
Pediatric Feeding Disorder: Consensus Definition and Conceptual FrameworkPraveen S Goday, Susanna Y Huh, Alan Silverman, et al.
International Journal of Epidemiology|March 19, 2014
Cohort profile: project vivaEmily Oken, Andrea A Baccarelli, Diane R Gold, et al.
Circulation|July 13, 2016
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria SyndromeLeslie B Gordon, Monica E Kleinman, Joe Massaro, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 2006
An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized ratsM K Kim, H D Kim, J H Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndromeLeslie B Gordon, Monica E Kleinman, David T Miller, et al.
Pageof 14